Hyperhomocysteinemia in chronic renal disease

Journal of the American Society of Nephrology

Volumn 10, Issue 4, 1999, Pages 891-900

  Bostom, Andrew G ^a   Culleton, Bruce F ^b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b Heart Lung Blood Institute's Heart   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ACETYLCYSTEINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B GROUP;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW;

EID: 0032984676     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v104891     Document Type: Review

References (94)

1. U.S. Renal Data System: USRDS Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1997
2. U.S. Department of Health and Human Services: Morbidity; and Mortality: Chartbook on Cardiovascular, Lung, and Blood Diseases, Bethesda, MD, U.S. Department of Health and Human Services, 1996
3. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: 112-119, 1998
4. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7: 158-165, 1996
5. Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA: Patient survival after renal transplantation. Nephrol Dial Transplant 12: 1672-1679, 1997
6. Luke RG: Chronic renal failure: A vasculopathic state [Editorial]. N Engl J Med 339: 841-843, 1998
7. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 84: 985-992, 1988
8. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 32: 853-905, 1998
9. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37: 1-31, 1985
10. Wilcken DE, Wilcken B: The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherited Metab Dis 20: 295-300, 1997
11. Omenn GS, Beresford SA, Motulsky AG: Preventing coronary heart disease: B vitamins and homocysteine [Editorial]. Circulation 97: 421-424, 1998
12. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057, 1995
13. Beresford SA, Boushey CJ: Homocysteine, folic acid, and cardiovascular disease risk. In: Preventive Nutrition: The Comprehensive Guide for Health Professionals, edited by Bendich A, Deckelbaum RJ, Totowa, NJ, Humana Press, 1997, pp 193-224
14. Food standards: Amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register 61: 8781-8797, 1996
15. Folic acid content of some grain foods is mandated by the FDA. Wall Street Journal, May 1, 1998
16. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138-141, 1998
17. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 17: 2554-2558, 1997
18. Jungers P, Chauveau P, Bandin O, Chadefaux B, Aupetit J, Labrunie M, Descamps-Latscha B, Kamoun P: Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 23: 170-173, 1997
19. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drucke TB, Legendre C, Lacour B, Kamoun P, Kreis H: Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 9: 1103-1108, 1994
20. Bostom AG, Gohh RY, Liaugaudas G, Beaulieu AJ, Han H, Jacques PF, Dworkin L, Rosenberg IH, Selhub J: Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. Atherosclerosis 1999, in press
21. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jacques PF, Selhub J, Rosenberg IH: Treatment of hyperhomocysteinemia in renal transplant recipients: A randomized, placebo-controlled trial. Ann Intern Med 127: 1089-1092, 1997
22. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH: Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 39: 1764-1779, 1993
23. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270: 2693-2698, 1993
24. Selhub J, Miller JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55: 131-138, 1992
25. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93: 7-9, 1996
26. Miller JW, Nadeau MR, Smith D, Selhub J: Vitamin B-6 deficiency vs folate deficiency: Comparison of responses to methionine loading in rats. Am J Clin Nutr 59: 1033-1039, 1994
27. Miller JW, Nadeau MR, Smith J, Smith D, Selhub J: Folate-deficiency-induced homocysteinaemia in rats: Disruption of S-adenosylmethionine's co-ordinate regulation of homocysteine metabolism. Biochem J 298: 415-419, 1994
28. Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B, Hamfelt A: Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: Effects of pyridoxine and folic acid treatment. Atherosclerosis 81: 51-60, 1990
29. Franken DG, Boers GH, Blom HJ, Trijbels JM: Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinaemia in vascular patients. J Inherited Metab Dis 17: 159-162, 1994
30. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ: The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 98: 177-184, 1996
31. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B: Homocysteine and cysteine: Determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 236: 633-641, 1994
32. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, Hopkins PN: Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 40: 552-561, 1994
33. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest JJ: Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits. Am J Clin Nutr 64: 587-593, 1996
34. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration. In: Metabolic Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw Hill, 1995, pp 1279-1313
35. Rosenblatt DS: Inherited disorders of folate transport and metabolism. In: Metabolic Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw Hill, 1995, pp 3111-3128
36. Linnel JC, Bhatt HR: Inherited disorders of cobalamin metabolism and their management. Ballieres Clin Haematol 8: 567-601, 1995
37. Guttormsen AB, Schneede J, Ueland PM, Refsum H: Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am J Clin Nutr 63: 194-202, 1996
38. Ducloux D, Fournier V, Rebibou JM, Bresson-Vautrin C, Gibey R, Chalopin JM: Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. Clin Nephrol 49: 232-235, 1998
39. Guttormsen AB, Ueland PM, Svarstad E, Refsum H: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 52: 495-502, 1997
40. House JD, Brosnan ME, Brosnan JT: Characterization of homocysteine metabolism in the rat kidney. Biochem J 328: 287-292, 1997
41. Foreman JW, Wald H, Blumberg G, Pepe LM, Segal S: Homocystine uptake in isolated rat renal cortical tubules. Metabolism 31: 613-619, 1982
42. Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J: Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116: 59-62, 1995
43. van Guldener C, Donker AJ, Jakobs C, Teerlink T, de Meer K, Stehouwer CD: No net renal extraction of homocysteine in fasting humans. Kidney Int 54: 166-169, 1998
44. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56: 41-46, 1996
45. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C: Plasma total homocysteine and cysteine in relation to GFR in diabetes mellitus. Kidney Int 1999, in press
46. Bostom AG, Gohh RY, Bausserman L, Hakas D, Jacques PF, Selhub J: Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J Am Soc Nephrol 10: 164-166, 1999
47. Wilcken DE, Gupta VJ, Betts AK: Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism. Clin Sci 61: 743-749, 1981
48. Bostom AG, Gohh RY, Tsai MY, Hopkins-Garcia BJ, Nadeau MR, Bianchi LA, Jacques PF, Rosenberg IH, Selhub J: Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol 17: 1894-1900, 1997
49. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 61: 509-512, 1996
50. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PW: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114: 93-103, 1995
51. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94: 2743-2748, 1996
52. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6: 121-125, 1995
53. Wilcken DE, Gupta VJ: Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 9: 301-307, 1979
54. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 40: 230-235, 1993
55. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 125: 91-101, 1996
56. McCully KS: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128, 1969
57. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 98: 204-210, 1998
58. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM: Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention. Arch Intern Med 158: 862-867, 1998
59. A'Brook R, Tavendale R, Tunstall-Pedoe H: Homocysteine and coronary risk in the general population: Analysis from the Scottish Heart Health Study and Scottish MONICA Surveys [Abstract]. Eur Heart J 19[Suppl]: 8, 1998
60. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337: 230-236, 1997
61. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PW: Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999, in press
62. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales LA, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277: 1775-1781, 1997
63. Meleady R, Lindgren A, Boers GH, Reis R, Wautrecht JC, Medrano M-J, Daly L, Graham IM: Plasma homocysteine as a prognostic risk factor for vascular disease [Abstract]. Eur Heart J 19[Suppl]: 8, 1998
64. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH: Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 17: 1947-1953, 1997
65. Peterson JC, Spence JD: Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia [Letter]. Lancet 351: 263, 1998
66. Chambers JC, McGregor A, Jean-Marie J, Kooner JS: Acute hyperhomocysteinaemia and endothelial dysfunction [Letter]. Lancet 351: 36-37, 1997
67. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98: 24-29, 1996
68. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O: Hyperhomocysteinemia-induced vascular damage in the minipig: Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 91: 1161-1174, 1995
69. Tracy RE, Strong JP, Newman WP, Malcom GT, Oalmann MC, Guzman MA: Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. Kidney Int 49: 564-570, 1996
70. Kasiske BL: Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 31: 1153-1159, 1987
71. Bostom AG, Bausserman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH: Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with a normal serum creatinine. Arterioscler Thromb Vasc Biol 1999, in press
72. Shemin D, Lapane KL, Bausserman L, Kanaan E, Kahn SI, Dworkin L, Bostom AG: Plasma total homocysteine levels and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol 1999, in press
73. Harker LA, Ross R, Slichter SJ, Scott CR: Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58: 731-741, 1976
74. Wall RT, Harlan JM, Harker LA, Striker GE: Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 18: 113-121, 1980
75. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262: 10098-10103, 1987
76. Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C: Abnormally high thromboxane biosynthesis in homozygous homocystinuria: Evidence for platelet involvement and probucolsensitive mechanism. J Clin Invest 92: 1400-1406, 1993
77. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1906-1914, 1991
78. Harpel PC, Chang VT, Borth W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89: 10193-10197, 1992
79. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 91: 6369-6373, 1994
80. Selhub J, D'Angelo A: Hyperhomocysteinemia and thrombosis: Acquired conditions. Thromb Haemostasis 78: 527-531, 1997
81. Mansoor MA, Ueland PM, Aarsland A, Svardal AM: Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. Metabolism 42: 1481-1485, 1993
82. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49: 147-152, 1996
83. Chauveau P, Chadefaux B, Coude M, Aupetit J, Kamoun P, Jungers P: Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 22: 106-109, 1996
84. Wilcken DE, Dudman NP, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37: 697-701, 1988
85. Janssen MJ, van Guldener C, de Jong GM, van den Berg M, Stehouwer CD, Donker AJ: Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 22: 110-114, 1996
86. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Jakobs C, Donker AJ, Stehouwer CD: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 13: 106-112, 1998
87. Arnadottir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40: 236-240, 1993
88. Bostom AG, Shemin D, Nadeau MR, Shih V, Stabler SP, Allen RH, Selhub J: Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation [Letter]. Atherosclerosis 113: 129-132, 1995
89. Hong SY, Yang DH, Chang SK: Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. Am J Nephrol 18: 367-372, 1998
90. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 8: 1899-1905, 1997
91. Bergstrom J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol 6: 1329-1341, 1995
92. Arnadottir M, Hultberg B: Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients. Transplantation 64: 1087, 1997
93. Malinow MR, Bostom AG, Krauss RM: Homocysteine, diet, and cardiovascular diseases: A statement for healthcare professionals. Circulation 99: 178-182, 1999
94. Kannel WB, Gordon T: The Framingham Study: An epidemiological investigation of cardiovascular disease (publication number 77-1247). 94-103. Washington, DC, Department of Health, Education, and Welfare, 1977